The Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee convened virtually on March 16 and 19, 2021 and reviewed the available information on thromboembolic events as well as thrombocytopenia following the use of AstraZeneca COVID-19 vaccine.

After careful scientific review, the subcommittee concluded that the AstraZeneca COVID-19 vaccine has a positive benefit-risk profile and can prevent infections and decrease deaths. The subcommittee further stated that according to the available data, there does not seem to be any overall increase in clotting conditions, including deep venous thrombosis or pulmonary embolism, after administration of COVID-19 vaccines. The reported rates of thromboembolic events following vaccination with the COVID-19 vaccines are in agreement with the expected number of diagnoses of these conditions… (WHO, March 19, 2021)